Legal & General Group Plc Purchases New Stake in ANI Pharmaceuticals, Inc. $ANIP

Legal & General Group Plc purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 45,075 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,731,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Penn Capital Management Company LLC raised its holdings in ANI Pharmaceuticals by 2,058.9% in the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after acquiring an additional 131,030 shares during the period. Vanguard Group Inc. lifted its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the last quarter. CenterBook Partners LP acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at $1,518,000. NFJ Investment Group LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at $2,766,000. Finally, Bank of America Corp DE grew its stake in shares of ANI Pharmaceuticals by 229.4% in the first quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock valued at $11,576,000 after acquiring an additional 104,828 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the transaction, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,925 shares of company stock valued at $1,890,145 over the last quarter. 8.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on ANIP shares. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $71.23 on Friday. The business has a 50 day moving average of $78.62 and a 200-day moving average of $78.44. The company has a market capitalization of $1.64 billion, a P/E ratio of 15.35 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the firm posted $1.80 EPS. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.